Yahoo · Sep 17, 2026
Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
The company is in the process of expanding the uses for its Hugo Surgical System and expanding its revenue base.
NYSE · ISRG
Intuitive Surgical, Inc.
Healthcare · Medical - Instruments & Supplies
$393.33
Up+$9.79 (+2.55%)
Updated Sep 20, 2026, 10:05 AM
SID Score
5.0/10
Composite research score
Smart Money
42/100
Neutral
- Market cap
- 195.51B
- P/E ratio
- 71.05
- Dividend yield
- 0.00%
- 52-week range
- $328.57 – $603.88
- Volume
- 4.93M
- Avg. volume
- 2.26M
Price performance
ISRG price history
1M range · 19 trading sessions · Daily adjusted prices
ISRG closed at $393.33 after 19 trading sessions, up 5.29% for the selected period.
- Last close
- $393.33
- Period change
- +5.29%
- Period low
- $350.16
- Period high
- $393.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $381.51 | $394.91 | $379.50 | $393.33 | 4.93M |
| Sep 17, 2026 | $385.57 | $388.20 | $378.2801 | $383.54 | 2.39M |
| Sep 16, 2026 | $378.00 | $387.29 | $377.16 | $382.29 | 2.14M |
| Sep 15, 2026 | $374.54 | $379.11 | $368.8501 | $377.16 | 1.98M |
| Sep 14, 2026 | $374.60 | $378.58 | $372.15 | $377.94 | 2.43M |
| Sep 11, 2026 | $363.56 | $374.48 | $363.56 | $369.15 | 3.35M |
| Sep 10, 2026 | $347.66 | $362.475 | $345.25 | $360.46 | 3.37M |
| Sep 9, 2026 | $350.20 | $357.99 | $349.855 | $353.24 | 2.42M |
| Sep 8, 2026 | $361.305 | $362.53 | $347.52 | $350.16 | 3.2M |
| Sep 4, 2026 | $367.81 | $369.55 | $363.23 | $366.70 | 2.08M |
| Sep 3, 2026 | $374.79 | $378.99 | $365.42 | $369.83 | 1.75M |
| Sep 2, 2026 | $369.00 | $382.41 | $368.25 | $371.88 | 2.05M |
| Sep 1, 2026 | $375.00 | $375.40 | $366.35 | $369.25 | 1.85M |
| Aug 31, 2026 | $369.00 | $377.37 | $365.3215 | $376.86 | 1.92M |
| Aug 28, 2026 | $368.00 | $373.395 | $366.735 | $372.60 | 1.8M |
| Aug 27, 2026 | $369.61 | $372.305 | $366.90 | $367.07 | 1.79M |
| Aug 26, 2026 | $368.49 | $372.372 | $366.73 | $370.42 | 1.67M |
| Aug 25, 2026 | $375.25 | $378.23 | $367.0701 | $371.84 | 1.77M |
| Aug 24, 2026 | $379.25 | $384.06 | $373.48 | $373.57 | 1.52M |
Latest ISRG news
The latest Smart Investors Daily articles mentioning ISRG.
Stock researchCompany · Overview
ISRG research
Overview
Company profile and research snapshot.
Company profile
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $618.00
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | BTIG | Buy | — |
| Aug 12, 2026 | Oppenheimer | Outperform | — |
| Jul 30, 2026 | HSBC | Hold | — |
| Jul 17, 2026 | Mizuho | Neutral | — |
| Jul 17, 2026 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 17, 2026
Is ISRG Stock Really As Expensive As It Looks?
Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.
Yahoo · Sep 17, 2026
3 Cash-Heavy Stocks to Research Further
Companies with more cash than debt often have stronger financial flexibility, making them attractive in uncertain markets. With interest payments less of a worry, these businesses can invest more in growth, innovation, or buybacks and dividends.
Yahoo · Sep 16, 2026
ISRG Wins EU Nod to Expand da Vinci SP in Gynecologic Procedures
Intuitive Surgical's CE mark expands da Vinci SP into transvaginal gynecology in Europe, opening a new women's health opportunity and growth runway.
AI research layers
Interpretive context generated from the platform’s current data sources.
Intuitive Surgical Stock Performance
Intuitive Surgical shares closed at $393.33, declining 0.85% in the most recent session, per SID market data. The stock has experienced broader weakness over the trailing twelve months, posting a negative 27.47% return, while shorter-term performance shows a 1.1% decline over the past month and a 3.31% loss over three months. Despite this extended drawdown, ISRG currently trades above its 50-day moving average of $373.49, suggesting a near-term technical recovery, though it remains well below its 200-day moving average of $443.51, indicating the longer-term downtrend persists. The 14-day RSI reads 62.8, positioning the stock in neutral-to-moderately bullish momentum territory without reaching overbought levels. Average daily trading volume stands at approximately 2.26 million shares, according to Massive/Polygon data. The company's beta of 1.686 reflects significantly higher volatility relative to the broader market, consistent with its growth-oriented investor base.
Intuitive Surgical Valuation Analysis
Intuitive Surgical carries a market capitalization of approximately $195.5 billion, commanding a premium valuation within the Healthcare sector, per SID market data. The company's price-to-earnings ratio stands at 71.05, reflecting elevated investor expectations for sustained future earnings growth from its dominant position in robotic-assisted surgery. The PEG ratio of 13.30 suggests the current P/E significantly exceeds the company's earnings growth rate, indicating the stock is priced at a substantial premium even when adjusting for growth, according to SEC filings. ISRG's price-to-book ratio of 11.53 further underscores the market's willingness to pay well above tangible asset value for the company's intellectual property, recurring revenue streams, and competitive moat. The company pays no dividend, directing capital instead toward research and development. These valuation metrics collectively place Intuitive Surgical among the most richly valued large-cap names in healthcare, reflecting its category-defining market position.
Smart Money Activity for ISRG
Intuitive Surgical's composite smart money score sits at 42 out of 100, reflecting a neutral overall signal, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating strong conviction among major fund managers and asset allocators who continue to hold significant positions. In contrast, insider activity scores 0 out of 25, the lowest possible reading. According to SEC Form 4 filings, there have been five insider transactions over the past 90 days, comprising just one purchase against four sales, suggesting company executives and directors have been net sellers of shares during this period. Dark pool activity registers a relatively low 5 out of 25, indicating limited off-exchange accumulation by institutional buyers. Congressional trading activity scores 12 out of 25, reflecting moderate engagement by members of Congress, per 13F institutional filings. The divergence between robust institutional ownership and persistent insider selling presents a notable contrast in stakeholder conviction levels surrounding ISRG's current valuation.
Intuitive Surgical Earnings Outlook
Intuitive Surgical has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the most recent quarter, ISRG posted earnings per share of $2.80 against a consensus estimate of $2.41, representing a positive surprise of $0.39, or approximately 16.2%. The prior quarter showed an even stronger beat, with actual EPS of $2.50 versus an estimate of $1.92, yielding a $0.58 surprise of roughly 30.2%. These results demonstrate robust operational execution and procedure volume growth exceeding analyst expectations. Looking ahead, Wall Street analysts project EPS of $2.41 for the upcoming quarter and $2.54 for the following period, per analyst estimates. The forward estimates suggest continued earnings expansion, though the magnitude of recent upside surprises has not yet been fully incorporated into consensus projections. The next earnings report is scheduled for July 21, 2026, which will provide further visibility into procedure adoption trends.
Wall Street Analyst Ratings for ISRG
Recent Wall Street analyst activity on Intuitive Surgical reflects a generally constructive but mixed outlook, per SID consensus data. On September 8, 2026, BTIG reiterated its Buy rating, maintaining confidence in the company's growth trajectory. Oppenheimer upgraded ISRG to Outperform from Perform on August 12, signaling renewed bullishness following strong quarterly results. However, HSBC downgraded the stock to Hold from Buy on July 30, suggesting valuation concerns at current levels, according to Wall Street analyst reports. Mizuho maintained its Neutral stance on July 17, while TD Cowen reiterated its Buy rating on the same date, reflecting divergent views among coverage analysts. The balance of recent actions tilts positive, with two Buy-equivalent ratings maintained, one upgrade to Outperform, one downgrade to Hold, and one Neutral reiteration. This distribution suggests the analyst community broadly recognizes Intuitive Surgical's fundamental strength but remains divided on whether current valuation levels offer sufficient upside potential for new positions.
